Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: Is it protective?

Current Breast Cancer Reports

Volumn 5, Issue 4, 2013, Pages 302-308

  Bedoschi, Giuliano ^a,b   Turan, Volkan ^a,b   Oktay, Kutluk ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Innovation Institute for Fertility Preservation   (United States)

Author keywords

Breast cancer; Chemotherapy; Clinical trials; Fertility preservation; GnRH agonist; Gonadal damage; Gonadal suppression

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GOSERELIN; LUTEINIZING HORMONE; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; SPHINGOSINE 1 PHOSPHATE; TRIPTORELIN;

AMENORRHEA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CRYOPRESERVATION; DOUBLE STRANDED DNA BREAK; DRUG SAFETY; DRUG UTILIZATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FEMALE INFERTILITY; FERTILITY PRESERVATION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OVARIAN RESERVE; OVARY DISEASE; OVARY FOLLICLE; OVARY FUNCTION; OVARY INSUFFICIENCY; PREGNANCY OUTCOME; PREMATURE OVARIAN FAILURE; PRIMORDIAL GERM CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84891843727     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-013-0123-y     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36:237-49.
3. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386-405.
4. • Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31:2500-10. The American Society of Clinical Oncology published an update of its 2006 guidelines on fertility preservation in cancer patients.
5. Ethics Committee of the American Society for Reproductive M. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83:1622-8. (Pubitemid 40824792)
6. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222-9. (Pubitemid 350100744)
7. Kim SS, Klemp J, Fabian C. Breast cancer and fertility preservation. Fertil Steril. 2011;95:1535-43.
8. Letourneau JM, Ebbel EE, Katz PP, et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012;118:1933-9.
9. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007;67:10159-62. (Pubitemid 350070787)
10. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging. 2011;3:782-93.
11. • Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5:172ra121. The authors demonstrated that impairment of DNA double strand breaks repair leads to oocyte aging in mice and humans. As a result, women with BRCA1 mutations have lower ovarian reserve and may be more susceptible to chemotherapy-induced infertility.
12. Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16:1547-51.
13. • Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381:805-16. The multicenter ATLAS trial demonstrated that the prolonged use of tamoxifen in hormone-positive receptors breast cancer patients reduces the recurrence and mortality rates. This extended delay to attempt childbearing can result in the further decline in ovarian reserve due to aging.
14. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril. 2013;99:1496-502.
15. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630-5.
16. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885-90. (Pubitemid 44536859)
17. Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet. 2012;29:503-5.
18. Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27:491-4.
19. Practice Committees of American Society for Reproductive M. Society for Assisted Reproductive T. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99:37-43.
20. Greve T, Schmidt KT, Kristensen SG, Ernst E, Andersen CY. Evaluation of the ovarian reserve in women transplanted with frozen and thawed ovarian cortical tissue. Fertil Steril. 2012;97:1394-98 e1391.
21. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981;1:1132-4. (Pubitemid 11105800)
22. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys. 1990;19:873-80. (Pubitemid 20345154)
23. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12:1044-54. (Pubitemid 350007016)
24. Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006;147:694-9. (Pubitemid 43112985)
25. Grundker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003;1:65. (Pubitemid 39130460)
26. Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000;6:1109-14.
27. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12:1055-66. (Pubitemid 350007017)
28. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol. 1987;19:159-62. (Pubitemid 17059373)
29. Leung PC, Cheng CK, Zhu XM. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol. 2003;202:145-53. (Pubitemid 36593406)
30. Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev. 2005;26:283-306.
31. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407. (Pubitemid 36565571)
32. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694-7.
33. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011;11, CD008018.
34. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95:906-14 e901-4.
35. Gerber B SH, Ricardo F, Maass D, Fischer N, Sommer HL, et al. ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). Abstract ID 34455. American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2009:15s. Available at: http://meetinglibrary.asco.org/ content/34455-65 Accessed June 3, 2013.
36. • Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334-41. The 24 month follow-up of ZORO trial, a prospective randomized trial that evaluated the use of Goserelin co-treatment on ovarian function after anthracycline/cyclophosphamide-based (with or without taxane) neoadjuvant chemotherapy. This study shows no fertility preservation benefit from GnRHa co-treatment.
37. •• Balkenende E, Dahhan T, van der Veen F, Goddijn M. Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function. Fertil Steril. 2011;96:e155-6. On this letter to the editor, the authors performed a new meta-analysis of a previously reported meta-analysis by Bedaiwy et al after excluding the controversial RCT published by Badawy et al and including the 24-month follow-up of the ZORO trial. In this new meta-analysis the authors concluded that there is insufficient evidence to consider co-treatment with GnRH analogues as an effective fertility preservation strategy.
38. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269-76.
39. Leonard RC AD, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 28:89s; 2010 (suppl 15) abstr 590.
40. • Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30:533-8. Well-designed RCT evaluating the efficacy of Goserelin co-treatment in breast cancer patients. Although this study was stopped for futility, it possesses multiple strengths.
41. •• Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121:78-86. Well-designed RCT evaluating the efficacy of GnRH analogue co-treatment before and during chemotherapy in hormone-negative breast cancer patients.
42. Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21:2052-60.